22 related articles for article (PubMed ID: 38650175)
1. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma.
Vallés-Martí A; Mantini G; Manoukian P; Waasdorp C; Sarasqueta AF; de Goeij-de Haas RR; Henneman AA; Piersma SR; Pham TV; Knol JC; Giovannetti E; Bijlsma MF; Jiménez CR
Cell Rep; 2023 Jun; 42(6):112581. PubMed ID: 37269289
[TBL] [Abstract][Full Text] [Related]
2. Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.
Humphrey ES; Su SP; Nagrial AM; Hochgräfe F; Pajic M; Lehrbach GM; Parton RG; Yap AS; Horvath LG; Chang DK; Biankin AV; Wu J; Daly RJ
Mol Cell Proteomics; 2016 Aug; 15(8):2671-85. PubMed ID: 27259358
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
5. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
van Alphen C; Cloos J; Beekhof R; Cucchi DGJ; Piersma SR; Knol JC; Henneman AA; Pham TV; van Meerloo J; Ossenkoppele GJ; Verheul HMW; Janssen JJWM; Jimenez CR
Mol Cell Proteomics; 2020 May; 19(5):884-899. PubMed ID: 32102969
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Murthy D; Attri KS; Singh PK
Front Physiol; 2018; 9():335. PubMed ID: 29670543
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
Mehra S; Deshpande N; Nagathihalli N
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503244
[TBL] [Abstract][Full Text] [Related]
8. Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact.
Gutiérrez ML; Muñoz-Bellvís L; Orfao A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503261
[TBL] [Abstract][Full Text] [Related]
9. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues.
Vallés-Martí A; de Goeij-de Haas RR; Henneman AA; Piersma SR; Pham TV; Knol JC; Verheij J; Dijk F; Halfwerk H; Giovannetti E; Jiménez CR; Bijlsma MF
Mol Oncol; 2024 Apr; ():. PubMed ID: 38650175
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
